Eagle Pharmaceut Financials
This page shows Eagle Pharmaceut (EGRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2022 annual data. Scores normalized against common benchmarks. How we calculate these scores
Eagle Pharmaceut has an operating margin of 25.6%, meaning the company retains $26 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from 1.6% the prior year.
Eagle Pharmaceut's revenue surged 84.6% year-over-year to $316.6M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Eagle Pharmaceut carries a low D/E ratio of 0.24, meaning only $0.24 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Eagle Pharmaceut's current ratio of 1.70 indicates adequate short-term liquidity, earning a score of 48/100. The company can meet its near-term obligations, though with limited headroom.
Eagle Pharmaceut converts 16.0% of revenue into free cash flow ($50.5M). This strong cash generation earns a score of 80/100.
Eagle Pharmaceut's ROE of 15.3% shows moderate profitability relative to equity, earning a score of 61/100.
Eagle Pharmaceut scores 2.14, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Eagle Pharmaceut passes 5 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Eagle Pharmaceut generates $1.42 in operating cash flow ($50.7M OCF vs $35.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Eagle Pharmaceut earns $20.0 in operating income for every $1 of interest expense ($81.0M vs $4.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Eagle Pharmaceut generated $316.6M in revenue in fiscal year 2022. This represents an increase of 84.6% from the prior year.
Eagle Pharmaceut's EBITDA was $81.6M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 2209.8% from the prior year.
Eagle Pharmaceut generated $50.5M in free cash flow in fiscal year 2022, representing cash available after capex. This represents an increase of 81.1% from the prior year.
Eagle Pharmaceut reported $35.6M in net income in fiscal year 2022. This represents an increase of 513.1% from the prior year.
Eagle Pharmaceut earned $2.73 per diluted share (EPS) in fiscal year 2022. This represents an increase of 513.6% from the prior year.
Eagle Pharmaceut held $55.3M in cash against $56.2M in long-term debt as of fiscal year 2022.
Eagle Pharmaceut's gross margin was 73.0% in fiscal year 2022, indicating the percentage of revenue retained after direct costs. This is down 8.6 percentage points from the prior year.
Eagle Pharmaceut's operating margin was 25.6% in fiscal year 2022, reflecting core business profitability. This is up 24.0 percentage points from the prior year.
Eagle Pharmaceut's net profit margin was 11.3% in fiscal year 2022, showing the share of revenue converted to profit. This is up 16.3 percentage points from the prior year.
Eagle Pharmaceut's ROE was 15.3% in fiscal year 2022, measuring profit generated per dollar of shareholder equity.
Eagle Pharmaceut invested $34.1M in research and development in fiscal year 2022. This represents a decrease of 33.5% from the prior year.
Eagle Pharmaceut spent $18.0M on share buybacks in fiscal year 2022, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 15.1% from the prior year.
Eagle Pharmaceut invested $178K in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents a decrease of 44.9% from the prior year.
EGRX Income Statement
| Metric | Q2'23 | Q1'23 | Q3'22 | Q4'21 | Q2'22 | Q1'22 | Q4'20 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $64.6M-2.5% | $66.3M+0.6% | $65.9M+55.7% | $42.3M-12.1% | $48.1M+16.7% | $41.2M-17.4% | $49.9M0.0% | $49.9M |
| Cost of Revenue | $16.9M-2.6% | $17.3M-17.1% | $20.9M+115.3% | $9.7M+22.6% | $7.9M-6.3% | $8.4M-14.2% | $9.8M+12.8% | $8.7M |
| Gross Profit | $47.8M-2.5% | $49.0M+8.8% | $45.0M+38.0% | $32.6M-18.9% | $40.2M+22.6% | $32.8M-18.1% | $40.1M-2.7% | $41.2M |
| R&D Expenses | $9.8M+6.1% | $9.3M-0.6% | $9.3M+146.3% | $3.8M-61.8% | $9.9M-30.6% | $14.3M+52.1% | $9.4M+94.6% | $4.8M |
| SG&A Expenses | $27.7M-1.1% | $28.0M+19.2% | $23.5M+15.4% | $20.3M+22.2% | $16.6M-16.3% | $19.9M+9.3% | $18.2M+2.8% | $17.7M |
| Operating Income | $10.3M-12.5% | $11.8M+24.4% | $9.5M+60.4% | $5.9M-45.5% | $10.8M+386.8% | -$3.8M-138.5% | $9.8M-36.5% | $15.4M |
| Interest Expense | $1.4M-4.5% | $1.5M+32.2% | $1.1M+190.4% | $395K-6.4% | $422K0.0% | $422K+2.2% | $413K-15.5% | $489K |
| Income Tax | $4.1M-7.7% | $4.5M+29.2% | $3.5M-53.3% | $7.4M+283.3% | $1.9M+9.9% | $1.8M-47.1% | $3.3M+78.5% | $1.9M |
| Net Income | $5.2M-10.2% | $5.8M+180.6% | -$7.1M-15.1% | -$6.2M-271.5% | $3.6M+958.0% | -$421K-105.2% | $8.1M+14.1% | $7.1M |
| EPS (Diluted) | $0.39-11.4% | $0.44+181.5% | $-0.54-14.9% | $-0.47-274.1% | $0.27+1000.0% | $-0.03-105.1% | $0.59+15.7% | $0.51 |
EGRX Balance Sheet
| Metric | Q2'23 | Q1'23 | Q3'22 | Q4'21 | Q2'22 | Q1'22 | Q4'20 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $404.8M-2.3% | $414.2M+7.2% | $386.4M+52.3% | $253.7M-4.0% | $264.2M+1.6% | $260.0M+2.7% | $253.2M+2.0% | $248.2M |
| Current Assets | $187.3M-2.7% | $192.5M+4.0% | $185.0M+7.2% | $172.6M-1.7% | $175.5M+7.0% | $164.0M-1.3% | $166.1M+1.4% | $163.8M |
| Cash & Equivalents | $15.4M-29.9% | $21.9M+42.3% | $15.4M-84.2% | $97.7M-10.2% | $108.7M+3.3% | $105.2M+2.0% | $103.2M+15.0% | $89.7M |
| Inventory | $42.5M-3.8% | $44.1M-30.9% | $63.9M+191.5% | $21.9M+164.1% | $8.3M+20.9% | $6.9M-15.0% | $8.1M+22.6% | $6.6M |
| Accounts Receivable | $115.1M+0.2% | $115.0M+18.6% | $96.9M+135.6% | $41.1M-21.9% | $52.7M+17.4% | $44.9M-12.2% | $51.1M-2.1% | $52.2M |
| Goodwill | $45.0M0.0% | $45.0M+7.7% | $41.8M+5.2% | $39.7M0.0% | $39.7M0.0% | $39.7M0.0% | $39.7M0.0% | $39.7M |
| Total Liabilities | $152.8M-10.8% | $171.3M+10.8% | $154.7M+100.1% | $77.3M+11.4% | $69.4M+0.7% | $68.9M+2.5% | $67.2M-10.9% | $75.4M |
| Current Liabilities | $86.6M-11.4% | $97.8M-19.7% | $121.8M+63.8% | $74.4M+66.5% | $44.7M+6.4% | $42.0M+10.2% | $38.1M-16.3% | $45.5M |
| Long-Term Debt | $61.9M-10.1% | $68.8M+160.4% | $26.4M | $0-100.0% | $21.4M-8.1% | $23.3M-7.5% | $25.1M-7.0% | $27.0M |
| Total Equity | $252.0M+3.8% | $242.8M+4.8% | $231.8M+31.4% | $176.5M-9.4% | $194.8M+2.0% | $191.1M+2.7% | $186.0M+7.7% | $172.8M |
| Retained Earnings | $122.4M+4.4% | $117.3M+13.5% | $103.3M+36.2% | $75.9M-13.5% | $87.7M+4.3% | $84.1M-0.5% | $84.5M+10.5% | $76.4M |
EGRX Cash Flow Statement
| Metric | Q2'23 | Q1'23 | Q3'22 | Q4'21 | Q2'22 | Q1'22 | Q4'20 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$126K+99.6% | -$33.5M-153.2% | -$13.2M-263.8% | $8.1M-6.0% | $8.6M-18.0% | $10.5M-47.0% | $19.8M+251.2% | $5.6M |
| Capital Expenditures | $6K-89.7% | $58K | $0-100.0% | $49K+142.6% | -$115K-129.9% | $384K+125.9% | $170K-15.4% | $201K |
| Free Cash Flow | -$132K+99.6% | -$33.6M-153.6% | -$13.2M-264.8% | $8.0M-5.3% | $8.5M-16.0% | $10.1M-48.5% | $19.6M+261.0% | $5.4M |
| Investing Cash Flow | -$6K+100.0% | -$12.6M-11.8% | -$11.2M-22832.7% | -$49K-142.6% | $115K+102.1% | -$5.4M-3067.1% | -$170K+15.4% | -$201K |
| Financing Cash Flow | -$6.4M-150.7% | $12.6M+283.7% | $3.3M+132.6% | -$10.1M-93.8% | -$5.2M-72.8% | -$3.0M+50.6% | -$6.1M+74.5% | -$24.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | $0-100.0% | $10.0M+15.1% | $8.6M+201.7% | $2.9M+100.1% | $1.4M-79.5% | $7.0M-69.6% | $23.0M |
EGRX Financial Ratios
| Metric | Q2'23 | Q1'23 | Q3'22 | Q4'21 | Q2'22 | Q1'22 | Q4'20 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.9%0.0pp | 73.9%+5.6pp | 68.3%-8.8pp | 77.1%-6.5pp | 83.6%+4.0pp | 79.5%-0.7pp | 80.3%-2.2pp | 82.5% |
| Operating Margin | 15.9%-1.8pp | 17.8%+3.4pp | 14.4%+0.4pp | 13.9%-8.5pp | 22.5%+31.6pp | -9.2%-28.8pp | 19.6%-11.3pp | 30.9% |
| Net Margin | 8.0%-0.7pp | 8.7%+19.5pp | -10.8%+3.8pp | -14.6%-22.1pp | 7.5%+8.5pp | -1.0%-17.2pp | 16.1%+2.0pp | 14.1% |
| Return on Equity | 2.1%-0.3pp | 2.4% | N/A | N/A | 1.8% | N/A | 4.3%+0.2pp | 4.1% |
| Return on Assets | 1.3%-0.1pp | 1.4%+3.2pp | -1.8%+0.6pp | -2.4%-3.8pp | 1.4%+1.5pp | -0.2%-3.3pp | 3.2%+0.3pp | 2.8% |
| Current Ratio | 2.16+0.2 | 1.97+0.4 | 1.52-0.8 | 2.32-1.6 | 3.93+0.0 | 3.91-0.5 | 4.36+0.8 | 3.60 |
| Debt-to-Equity | 0.25-0.0 | 0.28+0.2 | 0.11+0.1 | 0.00-0.1 | 0.11-0.0 | 0.12-0.0 | 0.14-0.0 | 0.16 |
| FCF Margin | -0.2%+50.4pp | -50.6%-30.5pp | -20.1%-39.1pp | 19.0%+1.4pp | 17.6%-6.9pp | 24.5%-14.8pp | 39.3%+28.4pp | 10.9% |
Similar Companies
Frequently Asked Questions
What is Eagle Pharmaceut's annual revenue?
Eagle Pharmaceut (EGRX) reported $316.6M in total revenue for fiscal year 2022. This represents a 84.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Eagle Pharmaceut's revenue growing?
Eagle Pharmaceut (EGRX) revenue grew by 84.6% year-over-year, from $171.5M to $316.6M in fiscal year 2022.
Is Eagle Pharmaceut profitable?
Yes, Eagle Pharmaceut (EGRX) reported a net income of $35.6M in fiscal year 2022, with a net profit margin of 11.3%.
What is Eagle Pharmaceut's earnings per share (EPS)?
Eagle Pharmaceut (EGRX) reported diluted earnings per share of $2.73 for fiscal year 2022. This represents a 513.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Eagle Pharmaceut's EBITDA?
Eagle Pharmaceut (EGRX) had EBITDA of $81.6M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Eagle Pharmaceut have?
As of fiscal year 2022, Eagle Pharmaceut (EGRX) had $55.3M in cash and equivalents against $56.2M in long-term debt.
What is Eagle Pharmaceut's gross margin?
Eagle Pharmaceut (EGRX) had a gross margin of 73.0% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.
What is Eagle Pharmaceut's operating margin?
Eagle Pharmaceut (EGRX) had an operating margin of 25.6% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.
What is Eagle Pharmaceut's net profit margin?
Eagle Pharmaceut (EGRX) had a net profit margin of 11.3% in fiscal year 2022, representing the share of revenue converted into profit after all expenses.
What is Eagle Pharmaceut's return on equity (ROE)?
Eagle Pharmaceut (EGRX) has a return on equity of 15.3% for fiscal year 2022, measuring how efficiently the company generates profit from shareholder equity.
What is Eagle Pharmaceut's free cash flow?
Eagle Pharmaceut (EGRX) generated $50.5M in free cash flow during fiscal year 2022. This represents a 81.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Eagle Pharmaceut's operating cash flow?
Eagle Pharmaceut (EGRX) generated $50.7M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.
What are Eagle Pharmaceut's total assets?
Eagle Pharmaceut (EGRX) had $406.2M in total assets as of fiscal year 2022, including both current and long-term assets.
What are Eagle Pharmaceut's capital expenditures?
Eagle Pharmaceut (EGRX) invested $178K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.
How much does Eagle Pharmaceut spend on research and development?
Eagle Pharmaceut (EGRX) invested $34.1M in research and development during fiscal year 2022.
Does Eagle Pharmaceut buy back shares?
Yes, Eagle Pharmaceut (EGRX) spent $18.0M on share buybacks during fiscal year 2022, returning capital to shareholders by reducing shares outstanding.
What is Eagle Pharmaceut's current ratio?
Eagle Pharmaceut (EGRX) had a current ratio of 1.70 as of fiscal year 2022, which is generally considered healthy.
What is Eagle Pharmaceut's debt-to-equity ratio?
Eagle Pharmaceut (EGRX) had a debt-to-equity ratio of 0.24 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Eagle Pharmaceut's return on assets (ROA)?
Eagle Pharmaceut (EGRX) had a return on assets of 8.8% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is Eagle Pharmaceut's Altman Z-Score?
Eagle Pharmaceut (EGRX) has an Altman Z-Score of 2.14, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Eagle Pharmaceut's Piotroski F-Score?
Eagle Pharmaceut (EGRX) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Eagle Pharmaceut's earnings high quality?
Eagle Pharmaceut (EGRX) has an earnings quality ratio of 1.42x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Eagle Pharmaceut cover its interest payments?
Eagle Pharmaceut (EGRX) has an interest coverage ratio of 20.0x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Eagle Pharmaceut?
Eagle Pharmaceut (EGRX) scores 81 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.